Figure 2

Tiziana Life Sciences, Ltd.

TSPO-PET scans from intranasal foralumab-treated MS patients showing marked reduction in microglial activation over a 6-month treatment period.

Format

PNG

Source

Tiziana Life Sciences Ltd.

Téléchargements